During this conference we will discuss the management of these low prognosis patients in greater detail. Notably, we will move beyond controlled ovarian stimulation to explore further the involvement of LH in personalizing the luteal phase and in male infertility. Also, on the agenda will be the extra-gonadal effect of LH, including potential immune-modulation at the endometrium.
Following the precedent set at last year’s conference, considerable time will be devoted to basic science, alongside such controversial issues as progesterone rise and pharmacogenomics. This year we have attracted prominent scientists from the worlds of endocrinology, andrology, immunology and embryology to take part in our engaging educational programme.